Embed Notice

HTML Code

<blockquote style="position: relative; padding-left: 55px;"><section><a href="https://poa.st/objects/4182c612-0a0e-437c-b53b-0f348e4b8530">Trevor Goodchild:verified::pondering_orb: (trevorgoodchild@poa.st)'s status on Tuesday, 31-Dec-2024 22:37:49 JST</a><a href="https://poa.st/users/TrevorGoodchild" title="trevorgoodchild@poa.st"><img src="https://gnusocial.jp/avatar/2078-48-20220726223205.webp" width="48" height="48" alt="Trevor Goodchild:verified::pondering_orb:" style="position: absolute; left: 0; top: 0;">Trevor Goodchild:verified::pondering_orb:</a><div><a href="https://poa.st/objects/c7358320-38ee-4a12-909c-25d0f380b25a" rel="in-reply-to">in reply to</a><ul><li></ul></div></section><article><a href="https://poa.st/users/lpheathen">@lpheathen</a> No info on the long term side effects and the adverse short-term GI ones are significant. There's also the risk of permanent gastroparesis, although rare.<br><br><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9821052/">pmc.ncbi.nlm.nih.gov/articles/PMC9821052/</a></article><footer><a rel="bookmark" href="https://gnusocial.jp/conversation/4287757#notice-8381567">In conversation</a><time datetime="2024-12-31T22:37:49+09:00" title="Tuesday, 31-Dec-2024 22:37:49 JST">about 5 months ago</time> <span>from <span><a href="https://poa.st/objects/4182c612-0a0e-437c-b53b-0f348e4b8530" rel="external" title="Sent from poa.st via ActivityPub">poa.st</a></span></span><a href="https://poa.st/objects/4182c612-0a0e-437c-b53b-0f348e4b8530">permalink</a><h4>Attachments</h4><ol><li><article><header><div>Domain not in remote thumbnail source whitelist: cdn.ncbi.nlm.nih.gov</div><h5><a href="https://pmc.ncbi.nlm.nih.gov:443/articles/PMC9821052/">Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus</a></h5><div></div></header><div>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI ...</div><footer></footer></article></li></ol></footer></blockquote>

Corresponding Notice

Embed this notice
Trevor Goodchild:verified::pondering_orb: (trevorgoodchild@poa.st)'s status on Tuesday, 31-Dec-2024 22:37:49 JSTTrevor Goodchild:verified::pondering_orb:
in reply to
- lpheathen
@lpheathen No info on the long term side effects and the adverse short-term GI ones are significant. There's also the risk of permanent gastroparesis, although rare.

pmc.ncbi.nlm.nih.gov/articles/PMC9821052/
In conversationabout 5 months ago from poa.stpermalink
Attachments
1. Domain not in remote thumbnail source whitelist: cdn.ncbi.nlm.nih.gov
  Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
  Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI ...

Public

Embed Notice

HTML Code

Corresponding Notice